• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

    4.158 -0.482 (-10.38%)
    Streaming Delayed Price Updated: 11:36 AM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Coya Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Proposed Public Offering of Common Stock
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
    Via ACCESS Newswire
    News headline image
    iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
    Via ACCESS Newswire
    News headline image
    Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    Via Get News
    News headline image
    Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
    Enters into Agreement with Bradley L. Radoff and Michael Torok 
    From Atea Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
    From Coya Therapeutics, Inc.
    Via Business Wire
    News headline image
    Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.